Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

paris/инфаркт

Ссылка сохраняется в буфер обмена
Страница 1 от 113 полученные результаты

Predicting sudden death in the population: the Paris Prospective Study I.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Sudden death was found to share the same set of usual risk factors as coronary events and therefore could not be specifically predicted in the population. It appears, however, that parental history of sudden death has not been investigated yet as a risk factor for sudden death. Therefore,

The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The efficacy and safety of a combination of Persantine and aspirin, of aspirin alone and of a placebo as a regimen for preventing reinfarction were compared in 2026 patients who had recovered from a documented acute myocardial infarction (MI) that had occurred 8 weeks to 5 years previously. Baseline

[Persantin and aspirin in coronary heart disease. The persantin-aspirin reinfarction study group (PARIS)].

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
In the Persantine-Aspirin Reinfarction Study (PARIS) trial 2026 persons who had recovered from myocardial infarction (MI) were randomized into three groups: Persantine plus Aspirin (PR/A) (n = 810); aspirin alone (ASA) (n = 810); placebo (PLBO) (n = 406). The average length of follow-up study was 41

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB). Metrics to accurately predict the occurrence of each respective event and

1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Background: The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization. Objective: We

Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) thrombotic risk score is a novel score for predicting the risk of coronary thrombotic events after percutaneous coronary intervention (PCI). We assessed the prognostic value of this score for mortality in patients

Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Whether the underlying risk of bleeding influences the associations between patterns of dual antiplatelet therapy (DAPT) cessation and adverse events after percutaneous coronary intervention is unknown.Patients enrolled in the prospective, international,

Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The aim of this study was to examine the association between dual-antiplatelet therapy (DAPT) cessation and cardiovascular risk after percutaneous coronary intervention in relation to age.Examination of outcomes by age after percutaneous coronary

Changes in reperfusion strategy over time for ST segment elevation myocardial infarction in the Greater Paris Area: results from the e-MUST Registry.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND ESC guidelines recommend a shorter (90 min) delay for the use of primary percutaneous intervention (pPCI) in patients presenting within the first 2h of pain onset. Using registry data on STEMI patients in the Greater Paris Area, we assessed changes between 2003 and 2008 in the rates of

Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE To compare the risk of sudden death and non-sudden death from myocardial infarction associated with the metabolic syndrome (MetS) in asymptomatic men. RESULTS The mortality status of 6,678 middle-aged men from the Paris Prospective Study I, who were free of diabetes and coronary heart

Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Data on geographical variations in dual antiplatelet therapy (DAPT) cessation and the impact on outcomes after percutaneous coronary intervention (PCI) are limited. We sought to evaluate geographical patterns of DAPT cessation and associated outcomes in patients undergoing PCI in the

Coronary heart disease in middle-aged Frenchmen. Comparisons between Paris Prospective Study, Seven Countries Study, and Pooling Project.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
A systematic comparison was made of the incidence rates of major coronary heart disease (CHD), defined as fatal and non-fatal myocardial infarction and probable CHD deaths, observed in the Paris Prospective Study, the European and American cohorts of the Seven Countries Study, and the populations of

Regular dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury: is it time to revisit PARIS?

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Increased activated Akt and eNOS expression coincide with this persistent cardioprotection. Emergent coronary reperfusion therapies are rarely carried out before considerable myocardial injury has occurred. Moreover, reperfusion after prolonged ischemia produces paradoxical

[Prehospital management of very elderly patients with ST segment elevation in Paris by mobile intensive care units (Samu)].

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
More and more elderly people are hospitalised with myocardial infarction. Little is known on their pre-hospital management. In 2001 and 2002, 105 patients aged 80 years or more with suspected ST elevation infarction were managed by the mobile intensive care unit system of the SAMU de Paris-Necker.

Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Abdominal (visceral) and overall obesity are both related to coronary heart disease mortality risk; however, the relative contribution of these 2 components of fat deposit in the etiology of sudden death is unknown. RESULTS We used the data from 7079 asymptomatic men of the Paris
Присоединяйтесь к нашей
странице facebook

Самая полная база данных о лекарственных травах, подтвержденная наукой

  • Работает на 55 языках
  • Травяные лекарства, подтвержденные наукой
  • Распознавание трав по изображению
  • Интерактивная карта GPS - отметьте травы на месте (скоро)
  • Прочтите научные публикации, связанные с вашим поиском
  • Ищите лекарственные травы по их действию
  • Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.

Google Play badgeApp Store badge